Assessment of the predictive power the radiation-induced lymphocyte apoptosis method in prostate cancer patients
- PMID: 39789068
- PMCID: PMC11718057
- DOI: 10.1038/s41598-024-81450-7
Assessment of the predictive power the radiation-induced lymphocyte apoptosis method in prostate cancer patients
Abstract
Due to the better survival of patients with tumorous diseases, it is increasingly important to predict the side effects of radiotherapy, for which the Radiation-Induced Lymphocyte Apoptosis (RILA) method is proving to be effective in multicentric studies. Prostate cancer is the leading cause of cancer-related deaths among men worldwide, which is usually treated with radiotherapy. We recruited 49 patients with localized prostate cancer and performed RILA measurements before radiotherapy. Patients were treated with CyberKnife (35-40 Gy) or high-dose-rate brachytherapy (1 × 21 Gy). We performed chromosome aberration test for five years and graded side effects, IPSS and QoL questionnaire scores were recorded. We found that RILA% correlated with the IPSS increase (p = 0.0016, r=-0.44), which was confirmed with negative binomial regression (p = 0.0013). The negative predictive value for severe urinary side effects according to the IPSS questionnaire was 87.9% at the lower tertile of RILA values. Chromosome aberrations also correlated with side effects, but when we built models including variables of baseline and treatment characteristics of the patients, RILA, and chromosome aberrations, only RILA predicted a late increase in IPSS score (p < 0.0001, adjusted R2 = 68%). The RILA method was shown to be predictive of urinary side effects especially of patient-reported outcomes.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Funding: This work was supported by the National Research, Development and Innovation Fund of the Ministry of Culture and Innovation under the National Laboratories Program (National Tumor Biology Laboratory (2022 − 2.1.1-NL-2022-00010)); the Hungarian Thematic Excellence Program (TKP2021-EGA-44) and the Investment in the Future (Development of Innovative Cancer Diagnostic and Therapeutic Procedures at the National Institute of Oncology (2020 − 1.1.6-JÖVŐ-2021-00008)) Grant Agreements with the National Research, Development and Innovation Office.
References
Publication types
MeSH terms
Grants and funding
- 2022-2.1.1-NL-2022-00010/National Research, Development and Innovation Fund
- 2020-1.1.6-JÖVŐ-2021-00008/National Research, Development and Innovation Fund
- 2020-1.1.6-JÖVŐ-2021-00008/National Research, Development and Innovation Fund
- 2022-2.1.1-NL-2022-00010/National Research, Development and Innovation Fund
- 2022-2.1.1-NL-2022-00010/National Research, Development and Innovation Fund
- 2022-2.1.1-NL-2022-00010/National Research, Development and Innovation Fund
- 2022-2.1.1-NL-2022-00010/National Research, Development and Innovation Fund
- 2022-2.1.1-NL-2022-00010/National Research, Development and Innovation Fund
- 2022-2.1.1-NL-2022-00010/National Research, Development and Innovation Fund
LinkOut - more resources
Full Text Sources
Medical
